Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02DJG
|
|||
| Former ID |
DIB015123
|
|||
| Drug Name |
LY-2189102
|
|||
| Synonyms |
Anti-IL-1 beta mAb (cardiovascular disease), Lilly; Anti IL-1 beta antibody (non-insulin dependent diabetes, rheumatoid athritis), Lilly
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Cardiovascular disease [ICD-11: BA00-BE2Z; ICD-10: I00-I99] | Phase 2 | [1] | |
| Company |
Eli lilly
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00942188) A Study of LY2189102 in Patients With Type 2 Diabetes. U.S. National Institutes of Health. | |||
| REF 2 | Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care. 2013Aug;36(8):2239-46. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.